mRNA疫苗龙头再次巨亏,或将启动裁员

生物科技馆
18 Feb

继2023年度亏损47.14亿美元之后,全球mRNA疫苗巨头Moderna公司在2024年再次收获巨额亏损。近日,Moderna公布了2024年财报:2024年全年总收入约为32亿美元,净亏损约为36亿美元。与2023年相比,虽然亏损额度有所缩减,但是Moderna的总收入也从2023年的68亿美元锐减至2024年的32亿美元,属于直接腰斩。更为要命的是,收入下降的趋势在2025年还将继续,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10